07

Dec

2022

16:30

GMT

11:30

EST

17:30

CET

Webinar

Clopidogrel or Ticagrelor: Why, When, for Whom?

Average (ratings)
No ratings
Your rating

Overview

Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the cornerstone of the management of acute coronary syndromes. Despite its proven benefits, the choice of P2Y12 inhibitors remain to be debated over the decades because of the differences in efficacy and safety profiles among these agents. In this 60-minute session by the ISCP focusing on the A to Z of CV Pharmacotherapy, we will examine the differences between clopidogrel and ticagrelor, the two most widely used P2Y12 inhibitors worldwide. We will also identify the patient groups who can benefit most and discuss the optimal treatment duration.

This session is the fifth in a series of six webinars from the ISCP focusing on the A to Z of CV Pharmacotherapy. Led by moderators Craig Beavers (USA) and Franco Cheng (Hong Kong), it includes a speaker presentation from Diana A Gorog (UK) and a discussion from panellist Sotiris Antoniou (UK) that will examine the difference between two widely used P2Y12 inhibitors, clopidogrel and ticagrelor, through consideration of real-world examples, live discussions and audience Q&A.

This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.

This is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP) and co-produced in collaboration with Radcliffe Cardiology. The ISCP has been provided support to deliver this webinar by AstraZeneca UK through an unrestricted educational grant to cover organizational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.

Faculty:


Diana Gorog

Diana Gorog


Sotiris Antoniou

Sotiris Antoniou


Franco Cheng

Franco Cheng


Craig Beavers

Craig Beavers

This webinar is supported by

Agenda

Clopidogrel or Ticagrelor: Why, When, for Whom?

11:30-12:30 ET/16:30-17:30 GMT/17:30-18:30 CET

- Welcome words
- Clopidogrel or Ticagrelor: Why, When, for Whom? Lecture by Dr Gorog
- Case 1 &2 Presentations & Panel Discussion
- Audience Q & A

Key Learning Objectives

  • To evaluate and understand which patients should and should not be prescribed with clopidogrel and ticagrelor and which patients groups might benefit most;
  • To review the pharmacokinetics of clopidogrel and ticagrelor and their potential drug-drug interactions;
  • To analyse special and regional issues that impact the use of this drug;
  • To apply evidence-based recommendations to two real world cases.

Target Audience

  • Cardiovascular team members - doctors, nurses, pharmacists
  • Family physicians
  • Internists

Faculty Biographies


Diana Gorog

Diana Gorog

Prof Diana Gorog holds academic appointments at the University of Hertfordshire and at the National Heart and Lung Institute of Imperial College, London, and is a full-time interventional consultant cardiologist at East and North Hertfordshire NHS Trust, UK.

View full profile

Sotiris Antoniou

Sotiris Antoniou

Mr Sotiris Antoniou is Consultant Pharmacist at Barts Heart Centre, part of Barts Health NHS Trust.

View full profile

Franco Cheng

Franco Cheng

Mr Franco Cheng is a lecturer at the Department of Pharmacolog

View full profile

Craig Beavers

Craig Beavers

Dr Craig Beavers graduated in 2009 from the University of Kentucky (UK) College of Pharmacy and completed a PGY1 pharmacy practice residency and a PGY2 cardiology pharmacy residency at UK Albert B.

View full profile